Steven et al.134found that GLP-1 receptor activation in platelets by linagliptin (a DPP-4 inhibitor) and liraglutide (a GLP-1 receptor agonist) significantly attenuated endotoxemia-induced microvascular thrombosis. The gene discussed is GLP1R; the disease is serum lipopolysaccharide activity.